Ribavirin Bioavailability After Telaprevir Exposure

Civil Hospices of Lyon

Status: Completed

Conditions: Hepatitis C

Treatments: Drug: Triple therapy

Study type: Observational

Funder types: Other

Identifiers

NCT02881034

69HCL16_0557

Details and patient eligibility

About

Anemia is more frequent in patients receiving telaprevir with pegylated-interferon/ribavirin than in those receiving pegylated-interferon/ribavirin alone. The objective was to measure the impact of telaprevir on ribavirin bioavailability and to assess the concomitant renal function.

Enrollment: 37 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with hepatitis C virus infection
• Previous non-response to pegylated-interferon/ribavirin therapy
• Re-treatment with pegylated-interferon/ribavirin and telaprevir

Exclusion criteria

• Decompensated liver cirrhosis

Trial design

37 participants in 1 patient group

Hepatitis C patients

Description:

Hepatitis C virus (HCV) infected patients with a previous non-response to pegylated-interferon/ribavirin therapy and re-treated with pegylated-interferon/ribavirin and telaprevir

Treatment:

Drug: Triple therapy